2024 SV Therapeutics Impact & ESG ReportRead More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotechRead More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 19 January 2021Portfolio NewsHillrom Announces Planned Acquisition Of Bardy Diagnostics, Inc.
- 12 January 2021Portfolio NewsArtios Pharma Appoints Abid Ansari as Chief Financial Officer
- 12 January 2021Portfolio NewsBoehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
- 11 January 2021Portfolio NewsA United Front to Improve Health Outcomes in Northeast Kansas: Healthify's Latest Partnership
- 6 January 2021Portfolio NewsRibometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics
- 4 January 2021Portfolio NewsCareSource and Healthify to Address Social Determinants of Health The two organizations will create a statewide accountable social service network.
- 16 December 2020Portfolio NewsEnara Bio adds further world‐class cell therapy and immuno‐oncology expertise to Senior Management Team and Scientific Advisory Board
- 15 December 2020SV NewsSV Health Investors Promotes Greg Madden to Managing Partner
- 9 December 2020Portfolio NewsEnara Bio relocates to The Oxford Science Park's newest facility to expand R&D capabilities in the search for novel cancer immunotherapies
- 3 December 2020Portfolio NewsMerck KGaA and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology
- 1 December 2020Portfolio NewsAdaptHealth Corp. Announces Acquisition of National HME Provider AeroCare Holdings Inc. and Updates Financial Guidance For 2021
- 23 November 2020Portfolio NewsCatamaran Bio Launches with $42 Million Financing to Develop Off-the-Shelf CAR-NK Cell Therapies to Treat Solid Tumors